Probiotics in atherosclerosis: a pilot study

Phase 2

Completed

• Conditions: atherosclerosis; 10003816; 10003216

• Registration Number: NL-OMON30643
• Lead Sponsor: Academisch Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

patients with ANCA associated vasculits
increased CD4+/CD28- T-cell counts

Exclusion Criteria

No significant immunosupressive therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- phenotype of the CD4+/CD28- T-cells<br /><br>- measurement of other lymphocyte subsets (NK cells en regulatory T-cells)<br /><br>these cells will be tested on specificity for HSP-60 antigen<br /><br>- quantitive measurement of circulating HSP-60 en HSP-60 antibodies<br /><br>- quantitive measurement of circulating interleuking 10<br /><br>- selected CD4+/CD28- T-cells stimulation tests with measurement of IL-10<br /><br>production and intracellular cytokins</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>